3 Boomerang Capital’s Portfolio Company Taps Accomplished Life Sciences Leader to Drive Next Phase of Growth, Further Strengthening Research & Discovery for Biotech & Pharma Developers
The original announcement can be viewed on PR NEWSWIRE.
NEW CASTLE, Del. and GREENWICH, Conn., July 9, 2025 — ABS Bio, Inc., (“ABS Bio” or “the Company”), a 3 Boomerang Capital (“3 Boomerang” or “3BC”) portfolio company and a leader in biospecimen sourcing, cell culture services, and biorepository solutions for the global pharmaceutical and biotechnology industry, today announced the appointment of Ehab Alramahy as President and Chief Executive Officer. Company founder Charles Saller, Ph.D., will step down from day-to-day leadership but continue serving on the Board of Directors.
Mr. Alramahy is a seasoned executive with a strong track record of driving commercial growth, building high-performing teams, and leading complex life science businesses across North America and Europe. He brings a powerful mix of scientific insight and strategic leadership, having previously led global divisions at BioIVT, Biosynth Group, and Bachem Group. His blend of hands-on technical experience and executive leadership uniquely positions him to guide ABS Bio’s next phase of growth.
“ABS Bio and 3 Boomerang Capital are thrilled to welcome Ehab Alramahy to this important role,” said John Chickosky, Executive Chairman of ABS Bio. “In our search for a successor, we prioritized deep domain expertise and a leadership style that reflects ABS Bio’s client-first culture. Ehab brings both to the table, and we are confident he will earn the trust of our team and our clients from day one.”
“I am honored to lead ABS Bio and excited to work alongside John, the Board, and the talented team to drive the Company forward,” said Ehab Alramahy, President and CEO of ABS Bio. “I am especially grateful to Charlie Saller for building such an exceptional organization and for remaining on the board to share his experience and counsel. ABS Bio has built a reputation for reliability and scientific excellence, and I look forward to expanding our impact across the biopharma industry.”
“ABS Bio has earned its place as a trusted partner to nearly all major pharma companies,” said Charles Saller. “Ehab’s experience, energy, and deep understanding of the scientific capabilities that make ABS Bio unique give me great confidence in the Company’s future.”
